-
Sector Analysis
United Kingdom (UK) Solar Photovoltaic (PV) Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
UK Solar Photovoltaic (PV) Market Report Overview The cumulative installed capacity for solar PV in the UK was 15.91GW in 2022. It is expected to achieve a CAGR of more than 11% during 2022-2035. The UK Solar Photovoltaic (PV) market research report offers comprehensive information and understanding of the solar PV market in the UK. The report discusses the renewable power market in the country and provides forecasts up to 2035. UK Solar PV Market Outlook, 2022-2035 (GW) Buy Full...
-
Sector Analysis
United Kingdom (UK) Wind Power Market Analysis by Size, Installed Capacity, Power Generation, Regulations, Key Players and Forecast to 2035
UK Wind Power Market Report Overview The cumulative installed capacity for wind power in the UK was 28.76 GW in 2022. It is expected to achieve a CAGR of more than 9% during 2022-2035. The UK Wind Power market research report offers comprehensive information and an understanding of the wind power market in the UK. The report discusses the renewable power market in the country and provides forecasts up to 2035. UK Wind Power Market Outlook, 2022-2035 (GW) Buy Full...
-
Company Profile
Coca-Cola Amatil Ltd – Company Profile
Coca-Cola Europacific Partners API Pty Ltd., a subsidiary of Coca-Cola Europacific Partners Plc, manufactures, distributes, and markets carbonated and non-carbonated beverages. The company’s product portfolio comprises carbonated soft drinks, sports and energy drinks, iced tea, fruit juices, sparkling beverages, flavored milk, coffee, tea, beer, cider, spirits and alcoholic beverages. It markets products under Coca-Cola, Sprite, Fanta and Pump brands. The company’s own brands include Lift, Kirks, Feral, Deep Spring, Miller Chill, Molson Coors, Barista, and Fuze Tea. Geographically, the company...
Add to Basket -
Product Insights
CCA – Double Ground Campus Expansion – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our CCA - Double Ground Campus Expansion - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
Erie CCA – Bayfront Place Mixed-Use Development – Pennsylvania
Equip yourself with the essential tools needed to make informed and profitable decisions with our Erie CCA - Bayfront Place Mixed-Use Development - Pennsylvania report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
Hip Reconstruction – Enovis Corp – CCA
GlobalData, the industry analysis specialist, has released its latest report: Hip Reconstruction - Enovis Corp - CCA. The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches. In addition, the final selling pricing of medical devices is also impacted by the discounting...
-
Company Profile
Puretech Health Plc – Company Profile
Puretech Health Plc (Puretech), a subsidiary of Royalty Pharma Plc, is a biotherapeutics company that discovers, develops, and commercializes drugs to treat lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders. The company is pipeline products include LYT-100 (deupirfenidone), targeting inflammation and fibrosis, lymphedema, and SARS-CoV-2 respiratory problems; LYT-200, a human monoclonal antibody for the treatment of pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA); and LYT-210, a gamma delta-1 T cell receptor against solid tumors. It is also...
Add to Basket -
Government & Regulation
Europe Renewable Energy Policy Handbook, 2023 Update
Europe Renewable Energy Policy Overview The European Union has adopted integrated policies to ensure its progress towards 2030 climate and energy targets and its international commitments under the Paris Agreement. All European Union (EU) member countries have designated targets by the EU to conform to international emission norms. Competitive bidding, Feed-in Tariffs (FITs), Feed-in premium, tax incentives, subsidies and grants are the most common supportive measures used in the region to promote the renewable energy. Another support mechanism is Net-metering....
-
Government & Regulation
United Kingdom (UK) Renewable Energy Policy Handbook, 2023 Update
"UK Renewable Energy Policy Handbook, 2023 Update” is among the latest country specific policy reports from GlobalData, the industry analysis specialist. The report offers comprehensive information on major policies governing the renewable energy market in the country and provides information on renewable policies/developments at a regional/municipal level. The report discusses renewable energy targets and plans along with the present policy framework, giving a fair idea of overall growth potential of the renewable energy industry. The report also provides major technology...
-
Product Insights
Net Present Value Model: Lytgobi
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Lytgobi Drug Details Futibatinib (Lytgobi) is...